Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (91-100 of 627) with videos related to

Pageof 63
Sort By:
Kidney360|October 17, 2022
A <i>Post Hoc</i> Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney DiseaseGirish N Nadkarni, Dipti Takale, Bruce Neal, et al.
European Heart Journal|June 4, 2008
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trialRenato D Lopes, Karen P Alexander, Gretchen Marcucci, et al.
Cardiovascular Diabetology|September 23, 2022
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failureSok Cin Tye, Niels Jongs, Steven G Coca, et al.
Kidney International|May 30, 2020
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetesJingWei Li, Bruce Neal, Vlado Perkovic, et al.
American Heart Journal|March 8, 2017
Cardioversion and subsequent quality of life and natural history of atrial fibrillationSean D Pokorney, Sunghee Kim, Laine Thomas, et al.
Journal of the American Heart Association|May 6, 2016
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) RegistryEmily C O'Brien, Sunghee Kim, Laine Thomas, et al.
American Heart Journal|February 3, 2015
Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research ConsortiumJonathan H Seltzer, J Rick Turner, Mary Jane Geiger, et al.
European Heart Journal|January 13, 2006
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarctionWei-Ching Chang, Padma Kaul, Yuling Fu, et al.
American Heart Journal|March 5, 2013
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary interventionCynthia M Westerhout, Karen S Pieper, Stefan K James, et al.
American Heart Journal|April 30, 2013
Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approachesSumeet Subherwal, E Magnus Ohman, Kenneth W Mahaffey, et al.
Pageof 63

Showing results (91-100 of 627) with videos related to

Sort By:
Pageof 63
Kidney360|October 17, 2022
A <i>Post Hoc</i> Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney DiseaseGirish N Nadkarni, Dipti Takale, Bruce Neal, et al.
European Heart Journal|June 4, 2008
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trialRenato D Lopes, Karen P Alexander, Gretchen Marcucci, et al.
Cardiovascular Diabetology|September 23, 2022
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failureSok Cin Tye, Niels Jongs, Steven G Coca, et al.
Kidney International|May 30, 2020
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetesJingWei Li, Bruce Neal, Vlado Perkovic, et al.
American Heart Journal|March 8, 2017
Cardioversion and subsequent quality of life and natural history of atrial fibrillationSean D Pokorney, Sunghee Kim, Laine Thomas, et al.
Journal of the American Heart Association|May 6, 2016
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) RegistryEmily C O'Brien, Sunghee Kim, Laine Thomas, et al.
American Heart Journal|February 3, 2015
Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research ConsortiumJonathan H Seltzer, J Rick Turner, Mary Jane Geiger, et al.
European Heart Journal|January 13, 2006
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarctionWei-Ching Chang, Padma Kaul, Yuling Fu, et al.
American Heart Journal|March 5, 2013
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary interventionCynthia M Westerhout, Karen S Pieper, Stefan K James, et al.
American Heart Journal|April 30, 2013
Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approachesSumeet Subherwal, E Magnus Ohman, Kenneth W Mahaffey, et al.
Pageof 63